ArticleScientific reports2025
Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Angiogenic Doping: Plausible Yet Difficult to Detect.Sports medicine (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral amyloid angiopathy (CAA) is a common yet underdiagnosed disease of the small brain vessels, resulting in acute vascular events as well as subcortical neurodegeneration. Currently, it is identified only at advanced stages due to the limitations of non-invasive diagnostic tools. Our pilot study evaluates metabolic and immune alterations in stroke patients with imaging-confirmed CAA. This prospective cohort study included stroke patients admitted to the University Hospital Erlangen with CAA diagnosis based on MRI findings. Metabolomic analysis of cerebrospinal fluid and serum samples was performed using liquid chromatography/mass spectrometry, focusing on caffeine metabolism and amino acid pathways. Immunophenotyping of leukocytes was conducted via flow cytometry. The study included 22 stroke patients, of whom 10 had an MRI-based diagnosis of CAA. Metabolomic analysis revealed consistently lower levels of caffeine-related metabolites in CAA patients with significant differences in 5-acetylamino-6-amino-3-methyluracil, paraxanthine, theobromine, 3,7-dimethyluric acid, 3-methylxanthine and 1-methylxanthine. Amino acid levels showed no significant differences. Immunophenotyping revealed a reduction in CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.